homologous recombination deficiency

August 4, 2020August 4, 2020

Study: Tests Used to Predict Response to PARP Inhibitors Yield Inconsistent Result

News

Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability to repair their DNA — a status termed “homologous recombination deficiency” (HRD), and likely would ... Read more

October 25, 2019

FDA Approves Zejula as Late-Line Treatment for Recurrent Ovarian Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a late-line treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have tumors defective in DNA ... Read more

April 15, 2019

Myriad Seeks FDA Approval of myChoice HRD CDx Diagnostic Test for Ovarian Cancer Patients

News

Myriad Genetics has submitted the first part of a premarket approval application with the U.S. Food and Drug Administration for myChoice HRD CDx, a diagnostic test designed to identify ovarian cancer ... Read more